Trial Profile
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Sorbitol
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 18 Nov 2017 Results published in the Clinical Pharmacology and Therapeutics
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 24 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.